The effect of alemtuzumab on neurodegeneration in relapsing-remitting multiple sclerosis: A five-year prospective mono-center study
We showed that neurodegeneration continued in RRMS patients under ALZ treatment, but it appeared to be limited to BPF and GM, and more pronounced in patients with disease activity. Our data suggest that patients who respond to ALZ treatment show signs of remyelination. OCT and SyMRI have potential to quantify measures of neurodegeneration that is affected by treatment intervention in RRMS.
Authors
- Jan Lycke (ORCID: https://orcid.org/0000-0002-7891-8466)
- Clas Malmeström (ORCID: https://orcid.org/0000-0003-2477-0088)
- Markus Axelsson (ORCID: https://orcid.org/0000-0003-2036-4007)
- Sofia Sandgren (ORCID: https://orcid.org/0000-0001-6206-3339)
- Lenka Novakova (ORCID: https://orcid.org/0000-0001-7899-6395)
- Anna Nordin (ORCID: https://orcid.org/0000-0003-3791-364X)
- Henrik Zetterberg (ORCID: https://orcid.org/0000-0003-3930-4354)
- Hemin Sabir
Institutions
- Sahlgrenska University Hospital (SE)
- Hallands sjukhus Kungsbacka (SE)
- UK Dementia Research Institute (GB)
- University College London (GB)
- University of Gothenburg (SE)
Publication Details
- Journal
- Multiple Sclerosis and Related Disorders
- Published
- 2024-09-13
- DOI
- https://doi.org/10.1016/j.msard.2024.105894
- Citations
- 3
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.27